Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial

International Journal of Cardiology

Volumn 182, Issue , 2015, Pages 459-465

  Winkel, Per ^a   Hilden, Jørgen ^b   Hansen, Jørgen Fischer ^c   Kastrup, Jens ^a   Kolmos, Hans Jørn ^d   Kjøller, Erik ^e   Jensen, Gorm Boje ^f   Skoog, Maria ^a   Lindschou, Jane ^a   Gluud, Christian ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Adverse effects; Adverse events; Cardiovascular mortality; Clarithromycin; Stable coronary heart disease; Statin

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN;

AGED; CAUSE OF DEATH; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DENMARK; FEMALE; FOLLOW UP; FORECASTING; HUMAN; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; STROKE; TRENDS;

AGED; ANTI-BACTERIAL AGENTS; CAUSE OF DEATH; CLARITHROMYCIN; CORONARY ARTERY DISEASE; DENMARK; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MORBIDITY; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STROKE;

EID: 84947201502     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.020     Document Type: Article

References (37)

1. C.M. Jespersen, B. Als-Nielsen, M. Damgaard, J.F. Hansen, S. Hansen, O.H. Helø, P. Hildebrandt, J. Hilden, G.B. Jensen, J. Kastrup, H.J. Kolmos, E. Kjøller, I. Lind, H. Nielsen, L. Petersen, C. Gluud, and CLARICOR Trial Group Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial BMJ 332 7532 2006 22 27
2. C. Gluud, B. Als-Nielsen, M. Damgaard, J. Fischer Hansen, S. Hansen, O.H. Helø, P. Hildebrandt, J. Hilden, G.B. Jensen, J. Kastrup, H.J. Kolmos, E. Kjøller, I. Lind, H. Nielsen, L. Petersen, C.M. Jespersen, and CLARICOR Trial Group Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease Cardiology 111 4 2008 280 287
3. G.B. Jensen, J. Hilden, B. Als-Nielsen, M. Damgaard, J.F. Hansen, S. Hansen, O.H. Helø, P. Hildebrandt, J. Kastrup, H.J. Kolmos, E. Kjøller, I. Lind, H. Nielsen, L. Petersen, C.M. Jespersen, C. Gluud, and CLARICOR Trial Group Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease J. Cardiovasc. Pharmacol. 55 2 2010 123 128
4. P. Winkel, J. Hilden, J. Fischer Hansen, P. Hildebrandt, J. Kastrup, H.J. Kolmos, E. Kjøller, C.M. Jespersen, C. Gluud, G.B. Jensen, and CLARICOR Trial Group Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology 118 1 2011 63 67
5. E. Kjøller, J. Hilden, P. Winkel, N.J. Frandsen, S. Galatius, G. Jensen, J. Kastrup, J.F. Hansen, H.J. Kolmos, C.M. Jespersen, P. Hildebrandt, C. Gluud, and CLARICOR Trial Group Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease J. Clin. Epidemiol. 65 4 2012 444 453
6. World Health Organisation. International statistical classification of diseases and related health problems. Geneva: WHO (2012), 1993.
7. E. Kjøller, J. Hilden, P. Winkel, S. Galatius, N.J. Frandsen, G.B. Jensen, J. Fischer Hansen, J. Kastrup, C.M. Jespersen, P. Hildebrandt, H.J. Kolmos, and C. Gluud Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial Am. Heart J. 168 2 2014 197 204 e4
8. P.D. Allison Survival Analysis Using SAS, a Practical Guide 1995 SAS Institute Inc. Cary, NC
9. M.J. Harutyunyan, A.B. Mathiasen, P. Winkel, J.P. Gøtze, J.F. Hansen, P. Hildebrandt, G.B. Jensen, J. Hilden, C.M. Jespersen, E. Kjøller, H.J. Kolmos, C. Gluud, J. Kastrup, and CLARICOR Trial Group High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial Scand. J. Clin. Lab. Invest. 71 1 2011 52 62
10. K.K. Iversen, B. Teisner, P. Winkel, C. Gluud, E. Kjøller, H.J. Kolmos, P.R. Hildebrandt, J. Hilden, J. Kastrup, and CLARICOR Trial Group Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial Atherosclerosis 214 1 2011 203 208
11. J. Kastrup, J.S. Johansen, P. Winkel, J.F. Hansen, P. Hildebrandt, G.B. Jensen, C.M. Jespersen, E. Kjøller, H.J. Kolmos, I. Lind, H. Nielsen, C. Gluud, and CLARICOR Trial Group High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease Eur. Heart J. 30 9 2009 1066 1072
12. S. Lyngbaek, P. Winkel, J.P. Gotze, J. Kastrup, C. Gluud, H.J. Kolmos, E. Kjoller, G.B. Jensen, J.F. Hansen, P. Hildebrandt, J. Hilden, and ClaRICOR Trial Group Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide Eur. J. Prev. Cardiol. 21 10 2014 1275 1284
13. K. Thorlund, G. Imberger, M. Walsh, R. Chu, C. Gluud, J. Wetterslev, G. Guyatt, P.J. Devereaux, and L. Thabane The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study PLoS One 6 10 2011 e25491
14. S. Schembri, P.A. Williamson, P.M. Short, A. Singanayagam, A. Akram, J. Taylor, A.T. Hill, and J.D. Chalmers Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies BMJ 346 2013 f1235
15. H. Svanstrøm, B. Pasternak, and A. Hviid Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study BMJ 349 2014 g4930
16. W.A. Ray, K.T. Murray, S. Meredith, S.S. Narasimhulu, K. Hall, and C.M. Stein Oral erythromycin and the risk of sudden death from cardiac causes N. Engl. J. Med. 351 11 2004 1089 1096
17. W.A. Ray, K.T. Murray, K. Hall, P.G. Arbogast, and C.M. Stein Azithromycin and the risk of cardiovascular death N. Engl. J. Med. 366 20 2012 1881 1890
18. S.S. Andersen, M.L. Hansen, M.L. Norgaard, F. Folke, E.L. Fosbol, S.Z. Abildstrom, J. Raunso, M. Madsen, L. Kober, G.H. Gislason, and C. Torp-Pedersen Clarithromycin use and risk of death in patients with ischemic heart disease Cardiology 116 2 2010 89 97
19. E. Kita, M. Sawaki, K. Mikasa, D. Oku, K. Hamada, K. Maeda, N. Narita, and S. Kashiba Proliferation of erythromycin-stimulated mouse peritoneal macrophages in the absence of exogenous growth factors Nat. Immun. 12 6 1993 326 338
20. C.S. Robbins, I. Hilgendorf, G.F. Weber, I. Theurl, Y. Iwamoto, J.L. Figueiredo, R. Gorbatov, G.K. Sukhova, L.M. Gerhardt, D. Smyth, C.C. Zavitz, E.A. Shikatani, M. Parsons, N. van Rooijen, H.Y. Lin, M. Husain, P. Libby, M. Nahrendorf, R. Weissleder, and F.K. Swirski Local proliferation dominates lesional macrophage accumulation in atherosclerosis Nat. Med. 19 9 2013 1166 1172
21. K. Togami, S. Chono, and K. Morimoto Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro Biol. Pharm. Bull. 36 9 2013 1494 1499
22. S.Z. Abildstrøm, C. Torp-Pedersen, and L. Køber Arrhythmic and sudden death in chronic ischemic heart disease - a review of epidemiological data Card. Electrophysiol. Rev. 6 1-2 2002 5 8
23. D.P. Zipes, A.J. Camm, M. Borggrefe, A.E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A.J. Moss, R.J. Myerburg, S.G. Priori, M.A. Quinones, D.M. Roden, M.J. Silka, C. Tracy, J.J. Blanc, A. Budaj, V. Dean, J.W. Deckers, C. Despres, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J.L. Tamargo, J.L. Zamorano, S.C. Smith Jr., A.K. Jacobs, C.D. Adams, E.M. Antman, J.L. Anderson, S.A. Hunt, J.L. Halperin, R. Nishimura, J.P. Ornato, R.L. Page, and B. Riegel ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary Eur. Heart J. 27 17 2006 2099 2140
24. M. Naghavi, P. Libby, E. Falk, S.W. Casscells, S. Litovsky, J. Rumberger, J.J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P.H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P.J. Fitzgerald, D.S. Siscovick, C.L. de Korte, M. Aikawa, K.E. Airaksinen, G. Assmann, C.R. Becker, J.H. Chesebro, A. Farb, Z.S. Galis, C. Jackson, I.K. Jang, W. Koenig, R.A. Lodder, K. March, J. Demirovic, M. Navab, S.G. Priori, M.D. Rekhter, R. Bahr, S.M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull Jr., R.S. Schwartz, R. Vogel, P.W. Serruys, G.K. Hansson, D.P. Faxon, S. Kaul, H. Drexler, P. Greenland, J.E. Muller, R. Virmani, P.M. Ridker, D.P. Zipes, P.K. Shah, and J.T. Willerson From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II Circulation 108 15 2003 1772 1778
25. M. Naghavi, P. Libby, E. Falk, S.W. Casscells, S. Litovsky, J. Rumberger, J.J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P.H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P.J. Fitzgerald, D.S. Siscovick, C.L. de Korte, M. Aikawa, K.E. Juhani Airaksinen, G. Assmann, C.R. Becker, J.H. Chesebro, A. Farb, Z.S. Galis, C. Jackson, I.K. Jang, W. Koenig, R.A. Lodder, K. March, J. Demirovic, M. Navab, S.G. Priori, M.D. Rekhter, R. Bahr, S.M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull Jr., R.S. Schwartz, R. Vogel, P.W. Serruys, G.K. Hansson, D.P. Faxon, S. Kaul, H. Drexler, P. Greenland, J.E. Muller, R. Virmani, P.M. Ridker, D.P. Zipes, P.K. Shah, and J.T. Willerson From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I Circulation 108 14 2003 1664 1672
26. P. Libby, and M. Aikawa Mechanisms of plaque stabilization with statins Am. J. Cardiol. 91 4A 2003 4B 8B
27. A. Link, T. Ayadhi, M. Bohm, and G. Nickenig Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome Eur. Heart J. 27 24 2006 2945 2955
28. C.M. Jespersen, H.J. Kolmos, N. Frydendall, J. Hilden, C. Gluud, J.F. Hansen, and CLARICOR Trial Group Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial J. Antimicrob. Chemother. 64 2 2009 411 415
29. Directive 2001/20/EC of the European Parliament and of the Council of 4 April on the approximation of the laws, regulations and administrative provisions of the Member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Off. J. L 121 2001 34 44
30. International Conference on Harmonisation Guideline for good clinical practice E6 (R1) http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf
31. K. Krleza-Jeric, A.W. Chan, K. Dickersin, I. Sim, J. Grimshaw, and C. Gluud Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1) BMJ 330 7497 2005 956 958
32. A. Lundh, S. Sismondo, J. Lexchin, O.A. Busuioc, and L. Bero Industry sponsorship and research outcome Cochrane Database Syst. Rev. 12 2012 MR000033
33. J. Savovic, H.E. Jones, D.G. Altman, R.J. Harris, P. Juni, J. Pildal, B. Als-Nielsen, E.M. Balk, C. Gluud, L.L. Gluud, J.P. Ioannidis, K.F. Schulz, R. Beynon, N.J. Welton, L. Wood, D. Moher, J.J. Deeks, and J.A. Sterne Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials Ann. Intern. Med. 157 6 2012 429 438
34. L. Wood, M. Egger, L.L. Gluud, K.F. Schulz, P. Juni, D.G. Altman, C. Gluud, R.M. Martin, A.J. Wood, and J.A. Sterne Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study BMJ 336 7644 2008 601 605
35. J.P.T. Higgins, and S. Green The Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration 2011 (www.cochrane-handbook.org)
36. N. Freemantle, M. Calvert, J. Wood, J. Eastaugh, and C. Griffin Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289 19 2003 2554 2559
37. G.H. Gislason, J.N. Rasmussen, S.Z. Abildstrøm, N. Gadsboll, P. Buch, J. Friberg, S. Rasmussen, L. Køber, S. Stender, M. Madsen, and C. Torp-Pedersen Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction Eur. Heart J. 27 10 2006 1153 1158